Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.39 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.37 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | MT-CO1 | P00395 | 1/20 | 0.34 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.34 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.33 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4511877 | 0.85 | CYP26A1 (0.36) | PTGS2CYP26A1CYP26B1PTGS1MT-CO1 | |
| SCHEMBL13613877 | 0.82 | LTB4R (0.39) | PTGS2CYP26A1CYP26B1APPLTB4R | |
| SCHEMBL13613895 | 0.80 | CYP26A1 (0.36) | CYP26A1CYP26B1 | |
| SCHEMBL13613834 | 0.79 | CYP26A1 (0.36) | CYP26A1CYP26B1 | |
| SCHEMBL4515529 | 0.75 | CYP26A1 (0.33) | CYP26A1CYP26B1MT-CO2 | |
| SCHEMBL13614253 | 0.74 | PTGS2 (0.43) | PTGS2CYP26A1CYP26B1PTGS1APP | |
| SCHEMBL13614075 | 0.72 | PTGS2 (0.37) | PTGS2PTGS1APPMT-CO1MT-CO2 | |
| SCHEMBL14524821 | 0.70 | PTGS2 (0.36) | PTGS2CYP26A1CYP26B1PTGS1MT-CO1 | |
| SCHEMBL4519574 | 0.67 | CYP26A1 (0.36) | CYP26A1CYP26B1LTB4RLTB4R2 | |
| SCHEMBL5736931 | 0.67 | CYP26A1 (0.37) | CYP26A1CYP26B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638648-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7468391-B2 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | ALLERGAN, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-7226951-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2007-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | CYP1A2, CYP2A7, CYP3A7 | PTGS2 394/4885CYP26A1 15/4885CYP26B1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.